Related Experiment Video
Updated: Jun 30, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of
Background:
Rituximab resistance is one of the great challenges in the treatment of diffuse large B-cell lymphoma (DLBCL), but relevant biomarkers and signalling pathways remain to be identified. Coptis chinensis and its active ingredients have antitumour effects; thus, the potential bioactive compounds and mechanisms through which Coptis chinensis acts against rituximab-resistant DLBCL are worth exploring.
Objective:
To elucidate the core genes involved in rituximab-resistant DLBCL and the potential therapeutic targets of candidate monomers of Coptis chinensis.
Methods:
Using the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP), the Similarity Ensemble Approach and Swiss Target Prediction, the main ingredients and pharmacological targets of Coptis chinensis were identified through database searches. Through the overlap between the pharmacological targets of Coptis chinensis and the core targets of rituximab-resistant DLBCL, we identified the targets of Coptis chinensis against rituximab-resistant DLBCL and constructed an active compound-target interaction network. The targets and their corresponding active ingredients of Coptis chinensis against rituximab-resistant DLBCL were molecularly docked.
Results:
Berberine, quercetin, epiberberine and palmatine, the active components of Coptis chinensis, have great potential for improving rituximab-resistant DLBCL via PIK3CG.
Conclusion:
This study revealed biomarkers and Coptis chinensis-associated molecular functions for rituximab-resistant DLBCL.
Insights
Coptis chinensis compounds like berberine show promise in overcoming rituximab resistance in diffuse large B-cell lymphoma (DLBCL). This study identifies key targets, offering potential new therapeutic strategies for this challenging cancer.
Area of Science:
- Pharmacology
- Oncology
- Systems Biology
Background:
- Rituximab resistance presents a significant challenge in treating diffuse large B-cell lymphoma (DLBCL).
- Identifying reliable biomarkers and signaling pathways is crucial for effective DLBCL treatment.
- Coptis chinensis exhibits antitumor properties, suggesting potential in addressing rituximab-resistant DLBCL.
Purpose of the Study:
- To identify core genes implicated in rituximab-resistant DLBCL.
- To explore potential therapeutic targets of Coptis chinensis monomers against rituximab-resistant DLBCL.
- To understand the molecular mechanisms underlying Coptis chinensis's efficacy.
Main Methods:
- Utilized Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) for compound and target identification.
- Employed Similarity Ensemble Approach and Swiss Target Prediction to analyze Coptis chinensis components.
- Constructed an active compound-target interaction network and performed molecular docking to validate findings.
Main Results:
- Identified berberine, quercetin, epiberberine, and palmatine as key active components of Coptis chinensis.
- Discovered PIK3CG as a potential therapeutic target for rituximab-resistant DLBCL.
- Demonstrated the potential of these compounds to overcome rituximab resistance via PIK3CG.
Conclusions:
- This research uncovers novel biomarkers associated with rituximab-resistant DLBCL.
- Highlights specific molecular functions of Coptis chinensis relevant to DLBCL treatment.
- Suggests Coptis chinensis as a potential source for developing new therapies against resistant DLBCL.
